Biologic

SAN DIEGO — Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a median of zero after the first month and at 12 months, according to a poster presented here.

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host of related toxicities and adverse effects — has long been a goal for rheumatologists.

WASHINGTON — Patients with juvenile idiopathic arthritis receive biologic disease-modifying antirheumatic drugs significantly sooner on public insurance vs. private, particularly if they have oligoarticular JIA, according to a speaker.

PHILADELPHIA — The current biologics for patients with COPD include anti-IL-5 therapies, dupilumab, tezepelumab and anti-IL-33 therapies, according to a presentation at the 2024 GOLD COPD International Conference.

INDIANAPOLIS — Verséa Ophthalmics recently has introduced several new technologies for eye care, including the Biovance 3L Ocular amniotic membrane allograft and the T-POC quantitative testing platform for ocular surface disease.

WASHINGTON — In this video, Namrata Singh, MD, MSCI, spotlights three important abstracts in rheumatoid arthritis presented at ACR Convergence 2024.

In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.

BOSTON — Among caregivers of children with asthma, 54% did not “strongly agree” or “agree” that biologics are safe, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Symptoms improved with mepolizumab after treatment with omalizumab failed for a patient with asthma who developed allergic bronchopulmonary aspergillosis, according to a poster presented at the CHEST Annual Meeting.

More patients with moderate to severe Crohn’s disease achieved histologic response at week 52 with mirikizumab vs. ustekinumab, regardless of prior biologic exposure, according to data presented at UEG Week.